Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar;18(3):188-195.
doi: 10.25122/jml-2024-0398.

A comparative exploration of monoamine neurotransmitter transport disorders: mechanisms, clinical manifestations, and therapeutic approaches

Rand Redwan Al Sari  1 , Husna Irfan Thalib  1 , Syeda Sobiah Imad  2 , Sariya Khan  1 , Shyma Haidar  1 , Bayan Mohammed Khair Al Zoabi  1 , Sahar Hamed Fadda  1 , Samratul Fuadah  1 , Hassan Abu Alwan  3 , Abdullah Alghobaishi  4
Affiliations
Review

A comparative exploration of monoamine neurotransmitter transport disorders: mechanisms, clinical manifestations, and therapeutic approaches

Rand Redwan Al Sari et al. J Med Life. 2025 Mar.

Abstract

Neurotransmitters play important roles in brain function, influencing cognition, movement, and behavior. Disruption in neurotransmitter biosynthesis, expression, transport, or function due to genetic mutations can lead to various neurological and psychiatric disorders with variable age of onset. Catecholamines like dopamine, norepinephrine, epinephrine, and serotonin are key monoamines transported by specific transporters, including the dopamine transporter (DAT) and the vesicular monoamine transporter 2 (VMAT2). Disorders that involve monoamine neurotransmitter transport include dopamine transporter deficiency syndrome (DTDS) and brain dopamine-serotonin vesicular disorders (PKDYS2). These rare syndromes manifest with movement disorders and neuropsychiatric symptoms. DTDS results from a mutation in the SLC6A3 gene affecting dopamine reuptake, while PKDYS2 involves a mutation in the SLC18A2 gene impairing the transport of dopamine and serotonin. This review provides a comparative analysis of the diagnostic approaches, the management strategies, and the outcomes for these distinct disorders.

Keywords: 5-HIAA, 5-Hydroxyindoleacetic Acid; AADC, Aromatic L-Amino Acid Decarboxylase; CSF, Cerebrospinal Fluid; DA, Dopamine; DAT, Dopamine Transporter; DTDS; DTDS, Dopamine Transporter Deficiency Syndrome; EEG, Electroencephalography; ENMG, Electroneuromyography and Nerve Conduction Studies; GAT-1, Gamma-Aminobutyric Acid (GABA) Transporter 1; HVA, Homovanillic Acid; MAO-A, Monoamine Oxidase A; MAO-B, Monoamine Oxidase B; NE, Norepinephrine; PKDYS1, Infantile-Onset Parkinsonism Dystonia 1; PKDYS2; PKDYS2, Infantile-Onset Parkinsonism Dystonia 2; SNP, Single Nucleotide Polymorphism; VMAT2, Vesicular Monoamine Transporter 2; WES, Whole Exome Sequencing; dopamine transporter; monoamine neurotransmitter transporters.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Overview of normal neurotransmission of dopamine and serotonin
Figure 2
Figure 2
Monoamine neurotransmitter disorders
See this image and copyright information in PMC

References

    1. Teleanu RI, Niculescu AG, Roza E, Vladâcenco O, Grumezescu AM, Teleanu DM. Neurotransmitters—key factors in neurological and neurodegenerative disorders of the central nervous system. Int J Mol Sci. 2022 May 25;23(11):5954. doi: 10.3390/ijms23115954. - DOI - PMC - PubMed
    1. Yousuf MS, Kerr BJ. The role of regulatory transporters in neuropathic pain. Adv Pharmacol. 2016 Jan 1;75:245–271. - PubMed
    1. Ng J, Barral S, Waddington SN, Kurian MA. Dopamine transporter deficiency syndrome (DTDS): expanding the clinical phenotype and precision medicine approaches. Cells. 2023 Jun 28;12(13):1737. doi: 10.3390/cells12131737. - DOI - PMC - PubMed
    1. Rilstone JJ, Alkhater RA, Minassian BA. Brain dopamine–serotonin vesicular transport disease and its treatment. N Engl J Med. 2013 Feb 7;368(6):543–50. doi: 10.1056/nejmoa1207281. - DOI - PubMed
    1. Kurian MA, Gissen P, Smith M, Heales SJ, Clayton PT. The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol. 2011 Aug 1;10(8):721–33. doi: 10.1016/S1474-4422(11)70141-7. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources